Physical Activity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease.


Journal

Medicine and science in sports and exercise
ISSN: 1530-0315
Titre abrégé: Med Sci Sports Exerc
Pays: United States
ID NLM: 8005433

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 12 12 2018
medline: 12 11 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) progression is variable and affects several disease domains, including decline in lung function, exercise capacity, muscle strength, and health status as well as changes in body composition. We aimed to assess the longitudinal association of physical activity (PA) with these a priori selected components of disease progression. We studied 114 COPD patients from the PAC-COPD cohort (94% male, mean [SD], 70 yr [8 yr] of age, 54 [16] forced expiratory volume in 1 s % predicted) at baseline and 2.6 yr (0.6 yr) later. Baseline PA was assessed by accelerometry. Multivariable general linear models were built to assess the association between PA and changes in lung function, functional exercise capacity, muscle strength, health status, and body composition. All models were adjusted for confounders and the respective baseline value of each measure. Per each 1000 steps higher baseline PA, forced expiratory volume in 1 s declined 7 mL less (P < 0.01), forced vital capacity 9 mL less (P = 0.03) and carbon monoxide diffusing capacity 0.10 mL·min·mm Hg less (P = 0.04), while the St George's Respiratory Questionnaire symptom domain deteriorated 0.4 points less (P = 0.03), per year follow-up. Physical activity was not associated with changes in functional exercise capacity, muscle strength, other domains of health status or body composition. Higher PA is associated with attenuated decline in lung function and reduced health status (symptoms domain) deterioration in moderate-to-very severe COPD patients.

Identifiants

pubmed: 30531289
doi: 10.1249/MSS.0000000000001859
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

833-840

Auteurs

Heleen Demeyer (H)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.
Department of Rehabilitation Sciences, KU Leuven-University of Leuven, Leuven, BELGIUM.

David Donaire-Gonzalez (D)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.

Elena Gimeno-Santos (E)

CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.
Respiratory Institute, Hospital Clinic de Barcelona, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

Maria A Ramon (MA)

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
Department of Pneumology, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.
Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, SPAIN.

Jordi DE Battle (J)

ISGlobal, Barcelona, SPAIN.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova i Santa Maria. IRBLLEIDA. Lleida, SPAIN.

Marta Benet (M)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.

Ignasi Serra (I)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.

Stefano Guerra (S)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.
Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ.

Eva Farrero (E)

Department of Pneumology, Hospital Universitari de Bellvitge, Barcelona, SPAIN.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, SPAIN.

Esther Rodriguez (E)

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
Department of Pneumology, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.
Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, SPAIN.

Jaume Ferrer (J)

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
Department of Pneumology, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.
Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, SPAIN.

Jaume Sauleda (J)

Department Pneumology, Hospital Universitari Son Espases, Palma Mallorca, SPAIN.
Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma Mallorca, SPAIN.

Eduard Monso (E)

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
Hospital Universitari Parc Tauli, Sabadell, SPAIN.

Joaquim Gea (J)

Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, SPAIN.
Department of Pneumology, Hospital del Mar, Barcelona, SPAIN.

Roberto Rodriguez-Roisin (R)

Department Pneumology, Hospital Universitari Son Espases, Palma Mallorca, SPAIN.

Alvar Agusti (A)

Respiratory Institute, Hospital Clinic de Barcelona, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Madrid, SPAIN.

Josep M Antó (JM)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, SPAIN.

Judith Garcia-Aymerich (J)

ISGlobal, Barcelona, SPAIN.
Universitat Pompeu Fabra (UPF), Barcelona, SPAIN.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, SPAIN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH